Trius Therapeutics to Present Data From Drug Development Programs at ICAAC

SAN DIEGO, Sept. 7 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today that the results of multiple studies from its drug development programs, including its lead antibiotic drug candidate torezolid phosphate (TR-701), will be presented in poster presentations at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Boston September 12-15. In addition to the results of clinical and nonclinical studies of torezolid phosphate, the posters highlight advances in Trius' preclinical GyrB and DHFR antibacterial and antifungal programs.

The presentations are as follows:

Sunday, September 12th

Poster Presentations 002 – Pharmacology of Oxazolidinones and Miscellaneous Antibacterial Agents (11:30 a.m. – 1:30 p.m.)

• A1-013: Absolute Bioavailability of TR-701 FA and Pharmacokinetics after Single and Multiple Intravenous Administration in Healthy Adult Subjects; P. Bien, P. Prokocimer, K.A. Munoz, C. Bethune
• A1-014: Population Pharmacokinetic Modeling of TR-700 in Patients with Complicated Skin and Skin Structure Infections; J. Mondick, P. Bien, C. De Anda, M. Gastonguay, P. Prokocimer

Monday, September 13th

Poster Presentation 080 – Antibiotic Therapy of Serious Bacterial Infections in Animal Models (11:15 a.m. – 1:15 p.m.)

• B-709: Anti-Virulence Effect of TR-700 on MRSA Strains Causing Complicated Skin and Skin Structure Infections (cSSTIs); J. M. Yamaki, T. Synold, A. Wong-Beringer

Poster Presentations 092 – Inhibitors of Metabolic Processes (11:15 a.m. – 1:15 p.m.)

• F1-834: Structure-based Design of Novel 7-substituted Diaminoquinazoline Antibacterial Agents Targeting Dihydrofolate Reductase (DHFR); M. Hilgers, T. Lam, J. Zhang, X. Li, Z. Chen, M. Trzoss, C. Creighton, L. Kohen, M. Cunningham, B. Kwan, K. Nelson, M. Stidham, V. Brown-Driver, K. Shaw, J. Finn
• F1-835: Structure-Based Design of New DHFR Antibacterial Agents (Part 1):  7-Aryl-2,4-Diaminoquinazolines SAR; X. Li, M. Hilgers, J. Zhang, Z. Chen, T. Lam, M. Trzoss, L. Kohen, C. Creighton, M. Cunningham, K. Nelson, B. Kwan, M. Stidham, V. Brown-Driver; K. Shaw, J. Finn
• F1-836: Structure-Based Design of New DHFR Antibacterial Agents (Part 2):  7-Benzimidazol-1-yl-2,4-Diaminoquinazolines SAR; J. Finn, T. Lam, J. Zhang, M. Hilgers, X. Li, M. Trzoss, L. Kohen, M. Cunningham, K. Nelson, M. Stidham, V. Brown-Driver, K. Shaw
• F1-837: Microbiological Profile of Novel 2,4-diaminoquinazoline DHFR Inhibitors; V. Brown-Driver, T. Lam, K. Nelson, A. Castellano, C. Creighton, J. Zhang, X. Li, Z. Chen, M. Trzoss, K. GC, E. Biller, M. Cunningham, M. Stidham, K. Shaw,  J. Finn
• F1-838: Advanced Microbiology and In Vivo Efficacy of Rx101005, a Novel 2,4-Diaminoquinazoline DHFR Inhibitor; V. Brown-Driver, T. Lam, A. Castellano, K. Nelson, K. Shaw, J. Finn

Poster Presentations 093 – New Antifungal Agents (11:15 a.m. – 1:15 p.m.)

• F1-855: Evaluation of Novel 2,4-Diaminoquinazoline Inhibitors of Candida albicans DHFR; M. Cunningham, M. Hilgers, B. Kwan, K. Nelson, T. Lam, J. Zhang, X. Li, Z. Chen, M. Trzoss, C. Creighton, L. Kohen K. Shaw, J. Finn

Tuesday, September 14th

Poster Presentations 169 – Antibiotic Resistance in Gram-Negative Bacteria Other than Enterobacteriacea (11:15 a.m. – 1:15 p.m.)

• C1-1426: Evidence for Multiple Functionality of Campylobacter jejuni DNA Gyrase in Chromosomal Replication; D. Bensen, A. Walters, M. Cunningham, L. Tari, K. Shaw, J. Finn

Poster Presentations 170 – Antibiotic Resistance in Staphylococcus aureus (11:15 a.m. – 1:15 p.m.)

• C1-1431: Elevated Linezolid Resistance in Clinical Staphylococcus aureus cfr Isolates is Associated with Co-Occurring Mutations in Ribosomal Protein L3; J. Locke, G. Morales, M. Hilgers, K. GC, M. Rahawi, J. J. Picazo, K. J. Shaw, J. Stein
• C1-1432: Structure-Activity Relationships of Diverse Oxazolidinones for Linezolid-Resistant Staphylococcus aureus Strains Possessing Ribosomal Mutations or the cfr Methyltransferase Gene; J. Locke, J. Finn, M. Hilgers, K. GC, M. Rahawi, G. Morales, J. J. Picazo, W. IM, K. Shaw, and J. Stein

Copies of these posters will be available on the Trius website following the ICAAC meeting: http://www.triusrx.com/trius-therapeutics-news-posters-publications-year.php.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead product candidate, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.

SOURCE Trius Therapeutics, Inc.